FDA Approves Avlayah for Neurologic Manifestations of Hunter Syndrome

Thu, 26 Mar 2026 03:17:19 +0000
Pharmaceuticals

The FDA has approved Avlayah (tividenofusp alfa-eknm) for the treatment of neurologic manifestations of Hunter syndrome in certain pediatric patients. This marks the first drug approval specifically targeting the neurological complications of this rare genetic disorder.